Daiichi Sankyo has launched a new direct-to-consumer (DTC) campaign for Enhertu — the first DTC effort for its oncology unit ...
The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...
Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...
GlobalData on MSN1d
NHS England to offer Daiichi Sankyo’s quizartinib for AMLThe UK Medicines and Healthcare products Regulatory Agency previously confirmed the asset’s safety and efficacy.
Osaka Metropolitan University researchers analyzed the incidence in Japan of COVID-19-associated pulmonary aspergillosis ...
As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up ...
Merck and Daiichi Sankyo announced. Oncternal Therapeutics announced termination of a clinical trial of the androgen receptor inhibitor ONCT-534 in metastatic castration resistant prostate cancer and ...
The FDA has approved Merck's Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for first-line ...
This summary covers significant updates in the health sector, including US Senator Bernie Sanders' push for cheaper generic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback